Education
About Us
Working with TipRanks
Follow Us
Humacyte (HUMA)
NASDAQ:HUMA
HUMA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.15 - $6.77
Previous CloseN/A
Volume1.64M
Average Volume (3M)3.27M
Market Cap
$279.55M
Enterprise Value$370.50M
Total Cash (Recent Filing)$38.03M
Total Debt (Recent Filing)$15.12M
Price to Earnings (P/E)―
Beta2.41
Next Earnings
Nov 07, 2025EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.24
Shares Outstanding158,835,300
10 Day Avg. Volume3,964,209
30 Day Avg. Volume3,273,012
Financial Highlights & Ratios
PEG Ratio-0.23
Price to Book (P/B)-11.36
Price to Sales (P/S)0.00
P/FCF Ratio-6.00
Enterprise Value/Market Cap1.33
Enterprise Value/Revenue46.05
Enterprise Value/Gross Profit865.64
Enterprise Value/Ebitda-9.92
Forecast
1Y Price Target
$6.20Price Target Upside246.37% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Bulls Say, Bears Say
Bulls Say
Military And Institutional Market AccessHUMA's clearance on the Electronic Catalog (ECAT) opens up Symvess to ~190 military facilities where Symvess will have increased utility in vascular trauma.
Product Launch And Market ExpansionThe company is poised to gain significant share for surgical procedures requiring vascular grafts, including reconstruction due to trauma, vascular access for dialysis patients, peripheral arterial disease repair, and, eventually, coronary artery bypass grafts and a BioVascular Pancreas (BVP).
Product Pricing And Market AdoptionThe recent lowering of Symvess price to $24,250 from prior $29,500 could potentially improve commercial momentum.
Bears Say
Financial Forecast And Revenue ExpectationsConsidering the weak 1H25 sales, the 2025 total revenues have been conservatively lowered to $2.5M from prior $10.4M.
Onboarding And Approval DelaysGetting the remainder of the hospitals through the entire process is taking longer than planned, however, now estimated at 6-9 months (up from 3-6 months).
Revenue And Financial PerformanceThe revenue reported for the second quarter was below both the internal estimate and the broader consensus estimate.
Humacyte News
HUMA FAQ
What was Humacyte’s price range in the past 12 months?
Humacyte lowest stock price was $1.15 and its highest was $6.77 in the past 12 months.
What is Humacyte’s market cap?
Humacyte’s market cap is $279.55M.
When is Humacyte’s upcoming earnings report date?
Humacyte’s upcoming earnings report date is Nov 07, 2025 which is in 34 days.
How were Humacyte’s earnings last quarter?
Humacyte released its earnings results on Aug 11, 2025. The company reported -$0.24 earnings per share for the quarter, missing the consensus estimate of -$0.162 by -$0.078.
Is Humacyte overvalued?
According to Wall Street analysts Humacyte’s price is currently Undervalued.
Does Humacyte pay dividends?
Humacyte does not currently pay dividends.
What is Humacyte’s EPS estimate?
Humacyte’s EPS estimate is -0.15.
How many shares outstanding does Humacyte have?
Humacyte has 158,835,300 shares outstanding.
What happened to Humacyte’s price movement after its last earnings report?
Humacyte reported an EPS of -$0.24 in its last earnings report, missing expectations of -$0.162. Following the earnings report the stock price went down -29.839%.
Which hedge fund is a major shareholder of Humacyte?
Currently, no hedge funds are holding shares in HUMA
Humacyte Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.20 (246.37% Upside)
$6.20 (246.37% Upside)
Blogger Sentiment
Bullish
HUMA Sentiment 75%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 5.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $7.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 2.2%
Last 30 Days ▼ 2.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-68.54%
12-Months-Change
Fundamentals
Return on Equity
-257.38%
Trailing 12-Months
Asset Growth
0.37%
Trailing 12-Months
Company Description
Humacyte
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. The company is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; and coronary artery bypass grafting, as well as developing its HAVs for pediatric heart surgery and cellular therapy delivery, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.
HUMA Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted significant progress in expanding Symvess approvals and sales, including entering military markets, and successful clinical trial results. However, challenges included a denial of CMS NTAP application and delays caused by public attacks.View all HUMA earnings summariesHUMA Stock 12 Month Forecast
Average Price Target
$6.20
▲(246.37% Upside)
Technical Analysis
Cartesian Therapeutics
―
Allogene Therapeutics
―
I-MAB
―
Foghorn Therapeutics
―
Kyverna Therapeutics, Inc.
―
Ownership Overview
1.93% Insiders
6.35% Mutual Funds
5.55% Other Institutional Investors
76.52% Public Companies and
Individual Investors